| scholarly article | Q13442814 |
| P2093 | author name string | Vincent A Fischetti | |
| Timothy K Vartanian | |||
| Kareem R Rumah | |||
| P2860 | cites work | The Myelin and Lymphocyte Protein MAL Is Required for Binding and Activity of Clostridium perfringens ε-Toxin | Q27319992 |
| Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion | Q28253124 | ||
| On dihydroorotate dehydrogenases and their inhibitors and uses | Q28286480 | ||
| Epsilon toxin: a fascinating pore-forming toxin | Q30155565 | ||
| Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study | Q33641367 | ||
| Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells | Q33982778 | ||
| Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite | Q34174973 | ||
| Sphingoid long chain bases prevent lung infection by Pseudomonas aeruginosa | Q34342508 | ||
| Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups | Q34735149 | ||
| Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease | Q35022730 | ||
| Gut microbiome and multiple sclerosis. | Q35245013 | ||
| Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro | Q35582048 | ||
| Clostridium perfringens Epsilon Toxin Causes Selective Death of Mature Oligodendrocytes and Central Nervous System Demyelination | Q35753667 | ||
| Antibacterial activity of sphingoid bases and fatty acids against Gram-positive and Gram-negative bacteria. | Q35806462 | ||
| Multiple sclerosis--the plaque and its pathogenesis | Q36410882 | ||
| Clostridium perfringens toxin genotypes in the feces of healthy North Americans | Q36745087 | ||
| Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening | Q36912176 | ||
| Menaquinone analogs inhibit growth of bacterial pathogens | Q37263504 | ||
| Teriflunomide and its mechanism of action in multiple sclerosis | Q37730005 | ||
| The interplay between the intestinal microbiota and the brain | Q38045736 | ||
| BG-12 in multiple sclerosis | Q38109572 | ||
| Inhibition of Clostridium botulinum 62A by fumarates and maleates and relationship of activity to some physicochemical constants | Q39923817 | ||
| Binding of epsilon-toxin from Clostridium perfringens in the nervous system | Q46649465 | ||
| Epsilon toxin from Clostridium perfringens acts on oligodendrocytes without forming pores, and causes demyelination | Q48495233 | ||
| Prediction of Michael-Type Acceptor Reactivity toward Glutathione | Q57004060 | ||
| The availability of sulphur for Clostridium perfringens and an examination of hydrogen sulphide production | Q74456628 | ||
| Combination therapy in multiple sclerosis | Q82972196 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Clostridium perfringens | Q309465 |
| P304 | page(s) | 11 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Frontiers in Cellular and Infection Microbiology | Q27724376 |
| P1476 | title | Oral Multiple Sclerosis Drugs Inhibit the In vitro Growth of Epsilon Toxin Producing Gut Bacterium, Clostridium perfringens | |
| P478 | volume | 7 |
| Q64055465 | Clostridium perfringens Epsilon Toxin Compromises the Blood-Brain Barrier in a Humanized Zebrafish Model |
| Q90653232 | Disease-modifying therapies alter gut microbial composition in MS |
| Q55236740 | Gut Microbiota in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Current Applications and Future Perspectives. |
| Q91198966 | Gut microbiome of treatment-naïve MS patients of different ethnicities early in disease course |
| Q91673342 | Gut microbiota composition during a 12-week intervention with delayed-release dimethyl fumarate in multiple sclerosis - a pilot trial |
| Q39434933 | Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis |
| Q92330463 | Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity |
| Q88961131 | The intestinal barrier in multiple sclerosis: implications for pathophysiology and therapeutics |
Search more.